Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group

Cardiovascular Diabetology

Volumn 16, Issue 1, 2017, Pages

  Schnell, Oliver ^a   Standl, Eberhard ^a   Catrinoiu, Doina ^b   Genovese, Stefano ^c   Lalic, Nebojsa ^d   Skra, Jan ^e   Valensi, Paul ^f   Rahelic, Dario ^g   Ceriello, Antonio ^c  

^a Forschergruppe Diabetes eV   (Germany)

^b Sf Ap Andrei County Clinical Emergency Hospital of Constanta   (Romania)

^c IRCCS MULTIMEDICA   (Italy)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITÉ PARIS 13   (France)

^g University of Zagreb School of Medicine   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HUMAN; LIFESTYLE MODIFICATION; NOTE; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG COST; ECONOMICS; EVIDENCE BASED MEDICINE; MORTALITY; PROTECTION; REIMBURSEMENT; RISK FACTOR; TREATMENT OUTCOME;

ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG COSTS; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE, HEALTH, REIMBURSEMENT; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 85014886914     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-017-0508-8     Document Type: Note

References (7)

1. Federal Drug Administration (FDA). Guidance for industry diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 20 Dec 2016.
2. European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Verfügbar unter. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf (2012). Accessed 10 Jan 2016.
3. Standl E, Schnell O, McGuire DK. Heart failure considerations of antihyperglycemic medications for type 2 diabetes. Circ Res. 2016;118(11):1830-43.
4. Zannad F, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-76.
5. Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28.
6. Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22.
7. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-44.